TAK Stock Recent News

Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q3 2025 Results Conference Call January 30, 2025 5:30 AM ET Company Participants Christopher O'Reilly - Head, Investor Relations Christophe Weber - President and Chief Executive Officer Milano Furuta - Chief Financial Officer Andy Plump - President, R&D Conference Call Participants Stephen Barker - Jefferies Hidemaru Yamaguchi - Citi Mike Nedelcovych - TD Cowen Hiroyuki Matsubara - Nomura Securities Tony Ren - Macquarie Shinichiro Muraoka - Morgan Stanley Seiji Wakao - J.P. Morgan Hiroshi Wada - SMBC Nikko Kazuaki Hashiguchi - Daiwa Securities Miki Sogi - Bernstein Fumiyoshi Sakai - UBS Christopher O'Reilly [Foreign Language] Let me start, I'd like to remind everyone that we'll be discussing forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

BOSTON--(BUSINESS WIRE)--Suffolk, one of the largest and most innovative real estate and construction enterprises in the country, recently celebrated topping off 585 Kendall. Designed by CBT Architects, 585 Kendall is a mixed-use lab/office building and performing arts center in the Canal District of Kendall Square. The event recognized the construction teams that played a vital role in reaching this significant milestone. Takeda has leased the property's approximately 600,000-square-foot of la.

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) announced today that its Board of Directors made the decision unanimously to appoint Julie Kim, currently president of Takeda's U.S. Business Unit, as the successor to Christophe Weber, Takeda's president, chief executive officer (CEO) and representative director, when Mr. Weber retires from the company in June 2026. Mrs. Kim will be proposed as a candidate for election to the Board at Takeda's Annual General Shareho.

Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates, as the company continues a restructuring push.

OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2024 (nine months ended December 31, 2024) showing continued advancement of its Growth & Launch Products, which delivered double-digit growth of 14.6% at CER. The company has upgraded its full year outlook for growth, reflecting strong year-to-date product performance and OPEX efficiencies, as well as revised foreign exchange assumptions. Takeda continues to adva.

-       Neurocrine Obtains Exclusive Worldwide Development and Commercialization Rights Excluding Japan and Converts to Royalty-Bearing License for Osavampator -       Takeda Reacquires Rights to Osavampator in Japan SAN DIEGO , Jan. 27, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it has amended its agreement with Takeda to develop and commercialize osavampator (NBI-1065845/TAK-653). Under the amended agreement, Neurocrine will obtain exclusive rights for all indications to develop and commercialize osavampator, a potential first-in-class AMPA positive allosteric modulator in development for patients with inadequate response to treatment of major depressive disorder (MDD) in all territories worldwide except Japan, where Takeda will reacquire exclusive rights.

Ascentage Pharma said on Thursday it aims to raise $126.4 million in an initial public offering in the United States, becoming the first sizeable Chinese firm to seek a listing in the U.S. this year.

China-based Ascentage Pharma said on Tuesday it was targeting a valuation of $1.75 billion in its initial public offering in the United States.

Takeda Pharmaceuticals (NYSE: TAK) offers a strong cash position and above-average dividend yield, making it an attractive option for income investors seeking international pharma exposure. The company's price/book value of 0.92 suggests it may be undervalued, presenting a potential long-term investment opportunity at a modest price. Risks include foreign currency exchange rate fluctuations and global pressure to reduce drug prices, which could impact profitability and margins.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.